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IntroductIon
A new version of chronic kidney dise-
ase (CKD) Guidelines, developed by 
KDIGO, was published in early 2013. 
The definition of CKD - kidney structu-
ral and/or functional abnormalities pre-
sent for more than three months - was 
maintained; and the words “with health 
implications” were added. The purpose 
of such change was to stress that the-
re may be a variety of abnormalities in 
kidney structure and function; howe-
ver, not all of them have undesirable 
clinical implications for an individual’s 
health, and thus need to be properly 
contextualized.
In the new version of the CKD 
Guidelines, they recommend to classify 
the disease based on the cause, in the 
glomerular filtration rate (GFR) class 
and albuminuria (Chart 1), which en-
ables the physician to identify the risks 
of adverse outcomes related to the renal 
impairment and death. They highlight 
the importance of establishing the cause 
of CKD - which is important to decide 
The authors of this "fast reading" 
present the data they have considered 
as more relevant in the KDIGO 2012 as 
concerned to evaluation and management 
of chronic kidney disease. The text does 
not correspond to their opinion, it is a 
brief presentation of guidelines that could 
be useful in clinical practice.
AbstrAct
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on the specific treatment in order to 
change risk estimates.
The instruction to estimate GFR from 
serum creatinine as the best method for 
the diagnosis, classification and treat-
ment of CKD progression was main-
tained. The GFR (in mL/min/1.73 m2) 
was divided into the classes G1 (> 89), 
G2 (60-89), G3a (45-60), G3b (30-44), 
G4 (15-29) and G5 (< 15).
They recommend the CKD-EPI 
equation to estimate GFR and they 
underscore the need to resort to other 
methods to confirm the diagnosis of 
CKD. For instance, KDIGO recom-
mends CKD diagnostic confirmation in 
adults with estimated GFR (eGFR) be-
tween 45-59 mL/min/1.73 m2 without 
other renal parenchyma lesions - either 
using serum cystatin C dosing, or pos-
sibly by means of a more specific test 
(e.g. exogenous markers of glomerular 
filtration).
Proteinuria or albuminuria (ideally 
expressed as mg/g of creatinine) was 
divided into A1 (or normal or slightly 
increased, when < 30 mg/g); A2 (or moder-
ately increased in the range of 30-300) and 
Amg/g3 (or markedly increased to values 
> 300 mg/g) - terminology replacing nor-
moalbuminuria, microalbuminuria and 
macroalbuminuria, previously adopted.
The big news of current CKD 
guidelines refers to the prominence 
given to the risk of adverse outcomes 
of the disease, based on the cause, the 
GFR, the amount of albuminuria and 
other concomitant medical conditions, 
from the work of the “CKD Prognosis 
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tAble 1 cKD cRiteRiA (Any one of the following  
 foR moRe thAn 3 months)
Kidney injury markers (one or more):
Albuminuria (> 30 mg/24h; creatinine/albumin ratio 30 
mg/g)
Abnormalities in urinary sediment
Electrolyte and other unbalances caused by tubular 
lesions
Abnormalities detected by histological exam
Structural abnormalities detected by image exam
Kidney transplant
Reduced GFR:
< 60 ml/min/1.73 m2 (GFR categories G3a-G5)
chArt 1 liKelihooD of chRonic KiDney DiseAse, bAseD on cAuse, glomeRulAR filtRAtion RAte AnD AlbuminuRiA
Cause Category eGFR* Albuminuria (proteinuria)**
*Glomerular disease 1 ≥ 90 A1 (< 30) A2 (30-300) A3 (> 300)
*Tubular-interstitial disease 2 60-89 - + ++
*Vascular disease
3a 45-59 + ++ +++
3b 30-45 ++ +++ +++
*Congenital disease 4 15-29 +++ +++ +++
*Cystic disease 5 < 15 +++ +++ +++
* eGFR: Estimated glomerular filtration rate in mL/min/1.73 m2; ** mg/g of creatinine. Risk for CKD: (-): Low risk (no CKD if there are no other 
markers of kidney injury); (+): Moderately increased risk; (++): High risk; (+++): Very high risk.
Consortium”, which evaluated data from 45 co-
horts in a total of 1,555,332 participants. Disease 
prognosis situations are presented, with the prob-
abilities of outcomes, such as mortality from all 
causes, cardiovascular mortality, progressive CKD, 
need for renal replacement therapy (RRT) and the 
impact of acute kidney injury in renal functional 
loss in the long run. Based on these situations, one 
can infer whether a patient has a greater or lower 
chance of, for instance, lose kidney function and 
require RRT. Thus, 70-year-old male with a GFR 
of 50 mL/min/1.73 m2 and without albuminuria 
(G3a/A1- according to the new classification) has a 
lower likelihood of needing RRT than a patient of 
55 years with a GFR of 70 mL/min/1.73 m2; albu-
minuria of 1.5 g/day (G2/A3). For example, in the 
case of the 70-year-old gentleman, more attention 
should be paid to the cardiovascular complications 
and less to the CKD progression.
Chart 1 chronic kidney disease probability, 
based on the cause, on the glomerular filtration 
rate and on albuminuria.
ckd dIAgnosIs
They reinforce criteria to be used for CKD diagno-
sis, which are presented on Table 1.
Throughout the Guidelines, the authors also 
present adjustments to the criteria to be adopted 
for children (considering the particularities of this 
group from birth to 18 years of age), whose refer-
ence ranges of laboratory results are differentiated.
It is important to remember that chronicity is 
not synonymous with irreversibility; therefore, the 
Guidelines take into account that some CKD cases 
may be reversible either spontaneously or with 
treatment.
Regarding renal function assessment, GFR - a 
component of the excretion function of the kid-
neys, is accepted as the best index for functional 
assessment, although the kidneys have many other 
functions, including endocrine and metabolic.
With regard to renal function markers, GFR es-
timates based on serum creatinine; but not serum 
creatinine alone, are sensitive enough to detect the 
measured GFR < 60 ml/min/1.73 m2, and can be 
confirmed by estimates using alternative markers 
or true GFR measures, if necessary. For various rea-
sons, focus has shifted from proteinuria quantifica-
tion into albuminuria (but not microalbuminuria). 
Albuminuria is the main component of urinary 
protein in most renal diseases, with which there has 
been a strong relationship with the kidney and car-
diovascular risks. Albuminuria is a common find-
ing, but it is not uniform in CKD.
Since 2002, several epidemiological studies have 
associated reduced GFR and albuminuria to the 
risk of adverse outcomes - which had not been pre-
viously considered CKD complications. Due to its 
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high prevalence, adverse outcomes and high costs 
of CKD, especially kidney failure, some countries 
have developed public healthcare programs for 
early detection and treatment of CKD and its com-
plications, and the effectiveness of these programs 
is under assessment.
Structural and functional kidney abnormalities 
may not have implications on the health of the indi-
vidual and therefore need to be contextualized. One 
should always consider factors specific to each case 
and not stagnant values from test results. It is note-
worthy that epidemiological studies have shown an 
increased prevalence of reduced eGFR and increased 
albuminuria/creatininuria ratio in older individuals; 
however, it is unclear whether this is in fact the dis-
ease or if it results from “normal aging”. Numerous 
studies have shown histopathological abnormali-
ties associated with aging, including glomerular 
sclerosis, tubular atrophy and vascular sclerosis. 
Regardless of the cause, these two conditions seem 
to be associated with increased risk of cardiovascu-
lar disease.
It is interesting to remember that healthy older 
individuals (without comorbidities) do not neces-
sarily have diminished GFR; and levels lower than 
60 ml/min/1.73 m2 are the exception.
Among the special circumstances relating to 
GFR, we stress the kidney donor, whose usual level 
of GFR after donation is approximately 70% of 
the pre-donation value - which is in the range of 
60-90 ml/min/1.73 m2 for most donors. When it 
is less than 60 ml/min/1.73 m2, there is a need for 
careful monitoring.
GFR is also affected by protein intake. Healthy 
adults with low protein intake may have lower GFR, 
but they usually have GFR < 60 ml/min/1.73 m2.
Albuminuria alone, without reduced GFR, may 
occur transiently in conditions other than CKD. 
It is considered that patients with persistent albu-
minuria have CKD. Albuminuria can be associated 
with obesity and metabolic syndrome, and remit 
with weight loss.
To prevent test interpretation to become highly 
complex, we adopted the albuminuria/creatinine 
threshold of 30 mg/g or about 3 mg/mmol, without 
corrections for gender and variations in creatinine 
excretion in order to detect diabetic nephropathy. 
It is interesting to notice that there is an increased 
risk for higher levels of albuminuria in all GFR cat-
egories without a clear threshold. Three categories 
of albuminuria are adopted, but it is known that 
the classification is arbitrary, since the risk relat-
ed with albuminuria is continuous. It is accepted 
that proteinuria in the nephrotic range confers 
additional risks.
However; the definition of GFR categories was 
deliberately based on the concept of ‘’true’’ GFR; 
however, in research and clinical practice they 
have predominantly used GFR estimates based on 
serum creatinine, which can cause inaccuracies, in-
cluding outcome differentiation between G1 (> 90 
ml/min/1.73 m2) and G2 (60-89 ml/min/1.73 m2) 
ranges. Studies with cystatin C found prognostic gra-
dients with eGFR levels above 60 ml/min/1.73 m2, 
supporting a role for both GFR categories in the 
CKD classification.
Albuminuria categories are “broader” in rela-
tion to risk, with significant gradients within each 
category, with only three proposals in these guide-
lines, as per stated above, given the need to simplify 
their implementation in clinical practice.
Methods to estIMAte And MeAsure renAl functIon
It is important that clinicians know several methods 
to estimate and measure kidney function and the 
situations in which specific methods may be superior 
in decision making regarding treatment and referral.
In general, GFR estimates may be used and 
in situations that are likely to be infrequent, and 
measurement may be necessary as in the evaluation 
of donor kidney function and in the use of toxic 
drugs with narrow therapeutic range.
It is recognized that no serum-creatinine-based 
equation will have great performance in all clini-
cal circumstances and that there may be changes 
in the performance of estimation equations over 
time and in different regions. It is emphasized that, 
for purposes of releasing estimated GFR results, 
it is important to select a single equation in a re-
gion or country. In North America, Europe and 
Australia, the advantages of the CKD-EPI equation 
at higher GFR ranges make it more relevant than 
the MDRD-study equation for general practice and 
public health care.
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It was commented that cystatin C use in eGFR 
equations would have some advantages over 
serum creatinine, but the test cost and potential 
lack of standardization between laboratories limit 
its recommendation as preferential and even as a 
second test after serum creatinine.
In regards to the assessment of albuminuria, it is 
suggested that the following measures for initial test-
ing of proteinuria be used, giving preference to the 
first urine sample of the morning (2B), in this order:
1. Albumin/creatinine ratio in urine (UACR);
2. Protein/creatinine ratio (PCR);
3. Urinalysis reagent strip for total protein with 
automatic reader;
4. Urinalysis reagent strip for total protein with 
manual reading.
It is recommended that clinical laboratories pro-
vide UACR and PCR in untimed samples of urine 
instead of isolated albuminuria and proteinuria 
(1B) results. Moreover, one should not over use the 
term “microalbuminuria”.
For proteinuria, the reference test is the 24-hour 
urine dosage, knowing; however, that it is difficult 
to control the procedure and inaccuracies in urine 
collection may contribute to errors in protein loss 
estimation.
It is noteworthy that in children, PRC is the best 
choice when compared to the UACR. For adults, 
albuminuria is considered more appropriate, which 
best predicts adverse outcomes.
Unlike in adults, in whom the CKD is pre-
dominantly attributed to glomerular disease or 
hypertensive lesion, most children have underlying 
condition such as congenital anomalies of the kid-
neys and the urinary tract. Thus, the relative scar-
city of glomerular diseases in children makes the 
albuminuria test less sensitive for diagnostic pur-
poses, since many children have underlying tubular 
diseases and tend to excrete more Tamm-Horsfall 
and other low-molecular-weight proteins that will 
not be shown by albuminuria detection tests.
ckd progress evAluAtIon
Lower GFR and higher albuminuria are both asso-
ciated with and increased progression rate and are 
synergistic. More frequent measurements of esti-
mated GFR and albuminuria should be considered 
in patients with lower GFR and higher albuminuria 
because of the greater likelihood of progression.
The frequency of assessments should be individ-
ualized based on the patient’s history and underly-
ing causes of kidney disease. Under specific condi-
tions, such as glomerulonephritis or increased levels 
of albuminuria, assessments should be carried out 
more frequently (every 1-3 months).
Another approach to progression takes into 
account the rate of change in kidney function based 
on the analysis of the creatinine “slope”, assessing 
the loss by changes in the absolute and relative 
rates. Less than 25% change between two GFR 
estimates may reflect physiological variation more 
than true disease progress.
GFR and albuminuria should be monitored at 
regular intervals to identify declining rates that 
exceed those normally observed. The GFR decline 
rate may be relatively constant over time in an 
individual.
Clinicians are encouraged to evaluate changes 
in GFR and albuminuria in the context of mul-
tiple observations over time and pay attention to 
clinical events that might impact these changes.
Repeated measurements of serum creatinine over 
time are less likely to contribute to the assessment 
of children when compared to adults, primarily 
by changes in muscle mass that occur in growing 
children.
Some factors that may predict CKD progres-
sion are modifiable, such as lifestyle changes (stop 
smoking and avoid obesity) and measures such 
as lowering blood pressure, albuminuria reduc-
tion and hyperglycemia prevention. It can also be 
changed based on the underlying causes of CKD, 
since various causes can respond to a specific treat-
ment, which should be considered in the first step 
(for example, immunosuppression).
ckd AssessMent
chRonicity evAluAtion
•	 In people with GFR < 60 ml/min/1.73 m2 
(G3a-G5) or markers of kidney injury, his-
tory and prior measurements should be 
reviewed to establish the kidney disease 
duration (no rating).
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•	 CKD is confirmed if the duration is > 3 months. 
One must follow the recommendations 
for CKD;
•	 If the length is not > 3 months or has not 
been established, CKD is not confirmed. 
Patients may have CKD or AKI or both, and 
the tests should be repeated.
Here, we are dealing with a definitive diagnosis 
of CKD with older measurements of renal function 
markers, proteinuria, imaging/ultrasound scans, 
biopsies, and other means.
Dosages should be repeated within a 3-month 
period and after that, to be sure about the CKD. 
The chronicity of this period cannot be established 
because the AKI may have such behavior.
evAluAtion of the cAuse
•	 One should evaluate the clinical context, in-
cluding personal and family history, environ-
mental factors, medications, physical exami-
nation, laboratory tests, imaging exams and 
histopathological diagnoses to determine the 
kidney disease causes (no rating).
We need to establish the CKD cause, using stan-
dard clinical methods (attention to the differential 
diagnoses of hypertension and diabetes).
Pediatric considerations
In the case of a child with GFR < 60 ml/min/1.73 m2 
or one standard deviation below the expected le-
vel for their age and gender, one should follow the 
guidelines established for adult patients. We must 
remember that kidney development abnormalities 
account for 30% to 50% of the causes of CKD in 
children.
gfR evAluAtion
KDIGO emphasizes the robust estimates of GFR 
determination, using standardized measures 
of creatinine, but it also emphasizes cystatin C 
measurement.
•	 The use of serum creatinine and its clearan-
ce is recommended to obtain the estimated 
GFR for initial investigation (1A);
•	 Additional tests are suggested (such as cysta-
tin C or its clearance) as confirmatory tests in 
specific circumstances when the GFR based 
on serum creatinine is less reliable (2B).”
There is no need to describe the estimated GFR 
using serum creatinine, considered good and ro-
bust. On the other hand, KDIGO describes the kid-
ney function alternative assessment with cystatin C 
or its clearance.
Pediatric considerations
For children, we should prefer the clearance esti-
mate instead of the simple use of serum creatinine 
on initial assessments, especially after the develop-
ment of the equation that incorporates the child’s 
height (Schwartz GI, 2009).
It is recommended that clinicians should (1B):
Use the GFR estimation equation derived from 
serum creatinine (eGFR) in place of serum creati-
nine alone;
Master the clinical situations where eGFR is less 
reliable.
GFR estimates were developed in serum creati-
nine stability/balance situations. We know that its 
serum levels is dependent on several factors, such as 
muscle generation, diet, tubular secretion and extra-
renal elimination from the gastrointestinal tract, fac-
tors that are not considered determinants of GFR.
When setting up a GFR estimation equation us-
ing a population, these non-determinant factors are 
included in obtaining the GFR, balancing their rel-
ative importance, i.e. they are computed with their 
effects, so that the eGFR results are better than pure 
measurement of serum creatinine, which may have 
been influenced to a greater degree by one or more 
GFR non-determinant factors. In other words, the 
eGFR is balanced by the mean population of the 
GFR non-determinant factors. Of course, in creati-
nine instability situations, errors in estimated GFR 
are larger.
Pediatric considerations
These recommendations are fully applicable in 
pediatrics.
Clinical laboratories should (1B):
•	 Dose serum creatinine using a specific assay 
with calibration related to the international 
reference and comparable with minimum 
methodology bias that uses isotope dilution 
mass spectrometry (IDMS);
•	 Include the eGFR in the report, together wi-
th the adult serum creatinine and specify the 
equation used;
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•	 Include the adult eGFR in the report using 
the 2009 CKD-EPI equation.
•	 If there is another equation, it is recommen-
ded that it be mentioned and it should have 
better accuracy compared to the CKD-EPI;
•	 Regarding serum creatinine, it is recommen-
ded that their results are rounded to the ne-
arest integer (mmol/l) or the 100th integer in 
conventional units (mg/dl);
•	 By including the eGFR in the report, it is 
recommended that it should be rounded up 
to the nearest integer and be associated to 
the body surface area of 1.73 m2 in adults, 
using ml/min/1.73 m2 units;
•	 It is recommended that eGFR < 60 ml/min 
be reported as decreased.
It is important to relate eGFR to the body surface, 
because it keeps a balanced ratio between GFR and 
kidney size. It should be remembered that 1.73 m2 
of body surface area corresponded to the mean body 
surface area of 25-year-old men and women from 
the U.S. in 1927. It is also important to keep in mind 
that drugs today are adjusted for GFR unrelated 
to body surface. There are no accurate studies on 
which correction would be better (with or without 
body surface).
Pediatric considerations
•	 The eGFR should be reported only when 
the height of the child is known to the 
laboratory.
•	 The laboratory shall report eGFR values < 60 
ml/min as reduced only in children over 2 
years of age.
•	 Cystatin C should be dosed in adults with 
eGFR 45-59 ml/min/1.73 m2 that have no 
marker of kidney damage when CKD con-
firmation is required (2C).
•	 If eGFRcys/eGFRcreat-cys is < 60 mL/min, 
CKD diagnosis is confirmed;
•	 If eGFRcys/eGFRcreat-cys is > 60 ml/min, 
CKD diagnosis is not confirmed.
There is evidence that cystatin C GFR estimates are 
better to predict mortality and cardiovascular events 
than estimates using creatinine. This is most apparent 
for clearances > 45 ml/min. Using the two formulas for 
obtaining clearance (cystatin C and serum creatinine), 
we obtain better result accuracy. Thus, the study 
group was in favor of using the eGFRcys. For popula-
tions with eGFRcreat < 60 ml/min/1.73 m2, mortality 
or terminal CKD forecasting increases significantly 
by adding eGFRcys and, especially, including the al-
bumin/creatinine ratio. By using CKD-EPI, we can 
greatly improve eGFR estimates using creatinine and 
cystatin C. The entire issue boils down to those pa-
tients with eGFR 45-59 ml/min which do not have 
markers of renal injury. Cystatin C clearances, both 
measured and estimated, have the same difficulties in 
obtaining than those using creatinine. Some countries 
use both methods. FDA approved cystatin C dosage 
to measure kidney function 10 years ago.
The study group only suggests that one can mea-
sure cystatin C, since its measurement is expensive 
and not available in much of the world. But they 
insist in such measure. The data, however, is not 
very convincing.
Pediatric considerations
This discussion has no relevance in pediatrics, gi-
ven that children with reduced GFR already have 
clear evidence of renal injury. In children, clearan-
ce discrepancies are visible only in those with high 
body weight.
If cystatin C is measured, it is suggested that the 
healthcare professional should:
•	 Use eGFRcys more than the isolated cystatin 
concentration;
•	 Understand situations where eGFRcys and 
eGFRcreat-cys are less reliable.
Clinical laboratories that measure cystatin 
should (1B):
•	 Dose it using a test with calibration refer-
enced to international standards;
•	 Report the eGFRcys result with serum 
cystatin in adults and specify the equa-
tion used whenever using eGFRcys and 
eGFRcreat-cys;
•	 Report eGFRcys and eGFRcreat-cys in 
adults, using the 2012 CKD-EPI formula 
for cystatin C or alternative formula for 
cystatin C if it shows better accuracy when 
compared to that of 2012.
When reporting serum cystatin C results:
•	 Provide cystatin C concentration results 
rounded to the nearest hundredth of an inte-
ger, expressed in conventional units (mg/l).
J Bras Nefrol 2014;36(1):63-73
Fast Reading of the KDIGO 2012: Guidelines for evaluation and management of chronic kidney disease in clinical practice
69
When reporting on eGFRcys and eGFRcreat-cys:
•	 They recommend that the results should be 
rounded to the nearest integer and associ-
ated with the body surface area of 1.73 m2 
in adults, using the ml/min/1.73 m2 units;
•	 They recommend to report as reduced the 
eGFRcys and eGFRcreat-cys lower than 60 
ml/min/1.73m2.
The 2012 equation using creatinine and cystatin 
has higher accuracy than the equations that use 
creatinine or cystatin alone.
Pediatric considerations
The following changes should be made (these 
assertions derive from the study of Schwartz in 
CkiD):
•	 Measure cystatin C by immunonephelometry;
•	 Report eGFRcys together with eGFRcreat;
•	 Report eGFR for children specifying the 
equation used.
It is suggested to measure the GFR using an ex-
ogenous marker in circumstances in which a more 
accurate result is required for treatment decisions. 
When this is necessary, it is important to know that:
•	 The GFR gold standard still is the test that 
uses inulin by continuous infusion;
•	 Errors in GFR measurement with exogenous 
markers are lower than those obtained by 
estimates.
fInAl reMArks
Not all laboratories can measure cystatin. It has 
been considered as an alternative due to the lar-
ge number of publications and their real benefits 
in some instances. Today, it is important but di-
fficult to obtain the standardization of cystatin C 
measurements.
Estimative methods are useful when dealing 
with epidemiological studies.
The best equation to use depends on the re-
gion and local custom, in Europe, the USA and 
Australia, CKD-EPI is considered a better equation 
than the MDRD equation.
mAnAging cKD pRogRession AnD complicAtions
Preventing ckd Progression
Chronic kidney disease (CKD) management aims 
to reduce a large number of elements associated 
with its progression, acting on different risk factors 
for cardiovascular disease (CVD), when approa-
ched separately or together with specific protection 
measures for CKD, directly or indirectly, will have 
a positive impact, slowing its progress.
Hypertension (HBP) control, blocking the 
renin-angiotensin system (RAAS) as well as 
better control of some metabolic parameters 
such as blood glucose, dyslipidemia, uric acid 
and acidosis, may have an important influence 
in delaying CKD development.
blooD pRessuRe AnD RAAs blocK
The adoption of “KDIGO Clinical Practice 
Guideline for the Management of Blood Pressure 
in CKD” is reinforced, being careful not to re-
commend or suggest very low blood pressure. The 
following are some recommendations:
•	 Individualize the goals of blood pressure 
control, as well as select agents to be used 
according to age, coexistence of CVD and 
other comorbidities, risk of progression to 
CKD, retinopathy (diabetic CKD) and tol-
erance to treatment (no rating);
•	 Always ask about vertigo and postural hypo-
tension when under the use of antihyperten-
sive drugs in the treatment of hypertension 
in patients with CKD (no rating);
•	 Individualize the treatment of hypertension 
in elderly patients with CKD, assessing co-
morbidities, other treatments, as well as the 
emergence of treatment-related side effects, 
such as electrolyte changes, abrupt worsen-
ing of renal function, postural hypotension 
and medication side effects;
•	 Treat adults with CKD, diabetic and nondia-
betic patients, with a urinary albumin ex-
cretion (UAE) ˂ 30 mg/24 h (or equivalent) 
with systolic blood pressure (SBP) consis-
tently ˃ 140 mmHg or diastolic blood pres-
sure (DBP) ˃ 90 mmHg, with antihyperten-
sive drugs to maintain SBP ≤ 140 mmHg 
and DBP ≤ 90 mmHg (1B);
•	 The guidelines suggest that adult CKD pa-
tients, diabetics and nondiabetics with UAE 
≥ 30 mg/24 h (or equivalent) and SBP ˃ 130 
mmHg or DBP 90 mmHg ˃  should be treated 
with antihypertensive drugs to maintain SBP 
≤ 130 mmHg and DBP ≤ 80 mmHg (2D);
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•	 They also suggested to use angiotensin convert-
ing enzyme inhibitor (ACEi) or angiotensin II 
receptor blocker (ARB II) in diabetic adults 
with CKD, who had UAE between 30-300 
mg/24h (2D);
•	 We recommend using ACEi or ARB II in 
diabetic adults with CKD and UAE ˃ 300 
mg/24 h; however, there is no evidence re-
garding the use of the association of the two 
classes of drugs in preventing CKD progres-
sion (1B);
•	 There is little evidence to recommend the 
combination of ACE inhibitors with ARB II 
to prevent CKD progression (no rating);
•	 It is recommended that in children with 
CKD, treatment for lowering blood pres-
sure should be initiated when it is consis-
tently above the 90th percentile for age, gen-
der and height (1C);
•	 It is suggested that children with CKD, espe-
cially if they have proteinuria, should have 
systolic and diastolic blood pressures main-
tained persistently below the 50th percentile 
for age, gender and height, unless they de-
velop symptoms of hypotension (2D);
•	 We suggest the use of ACEi or ARB II in chil-
dren with CKD in which the use of antihy-
pertensive drugs is indicated, regardless of 
the level of proteinuria (2D).
cKD AnD the RisK of Acute KiDney injuRy
It is recommended that all CKD patients should be 
considered at high risk for developing acute kidney 
injury (AKI) (1A);
In CKD patients, more attention should be giv-
en when suffering from some other diseases, as well 
as when undergoing procedures that are known to 
increase the risk of AKI (no rating).
Several studies have shown a strong epidemio-
logical association between CKD and AKI; CKD 
is a powerful predictor of acute decline in renal 
function after the use of iodinated contrast, ma-
jor surgery and certain other conditions. Diabetes 
mellitus, hypertension, and proteinuria increase 
the likelihood of AKI development in hospitalized 
patients.
pRotein intAKe
The role of dietary protein restriction aimed at 
slowing the progression of CKD is controversial, 
as described in a large number of reviews and 
meta-analyzes performed in diabetic and non-dia-
betic patients, but in all of them, compliance with 
low-protein diets was very poor, it is therefore not 
possible to convincingly conclude that long stan-
ding protein restriction delays CKD progression.
•	 A protein intake of 0.8 mg/kg/day is suggest-
ed for adults with diabetes (2C) or without 
diabetes (2B) and GFR ˂ 30 ml/min/1.73 m2 
(categories G4 and G5);
•	 Adult patients with CKD and at a high risk 
of progression should avoid higher protein 
intake (˃ 1.3 g/kg/day) in (2C).
glucose contRol
Diabetes mellitus is a major cause of CKD in the 
world and an independent risk factor for cardiovas-
cular disease (CVD), with mortality rates that dou-
ble in patients with creatinine/ albumin ratios (CAR) 
˃ 30 mg/g, which makes it important to have ade-
quate treatment in order to prevent microvascular 
injury. There still are controversies as to the intensity 
of glycemic control to be established, with large stu-
dies showing different results, both for and against 
stricter glycemic control.
•	 It is recommended to set a hemoglobin A1c 
(HbA1c) target of ~ 7.0% to prevent or 
slow the progression of microvascular com-
plications from diabetes, including diabetic 
nephropathy (1A);
•	 One should be very careful when trying to 
treat to achieve an HbA1c ˂ 7.0% target in 
patients at risk of hypoglycemia and also in 
the interpretation of their levels in CKD pa-
tients due to decreased survival of red blood 
cells in this population (1B);
•	 The HbA1c target should be above 7.0% in 
individuals with comorbidities or limited life 
expectancy and risk of hypoglycemia (2C).
Glucose control should be part of a multifacto-
rial intervention strategy In individuals with CKD 
and diabetes, addressing the control of blood pres-
sure and cardiovascular risk by promoting the use 
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of ACE inhibitors or ARB II, statins and antiplate-
let agents, when indicated (no rating).
sAlt intAKe
A deficiency in sodium excretion is often present 
in patients with CKD, causing elevation of blood 
pressure and proteinuria, glomerular hyperfiltra-
tion and further reduced response to the RAAS 
blockade. It is recommended to:
•	 Reduce intake to ˂ 2 g per day of sodium 
(corresponding to 5g of sodium chloride) 
in adults, unless contraindicated i.e. in pa-
tients with salt-depleting nephropathy, pos-
tural hypotension and volume contraction 
without heart failure (1C);
•	 Sodium intake Restriction for children with 
CKD who have hypertension (systolic and/or 
diastolic ˃ 95th percentile) or prehyperten-
sion (SBP and/or DBP ˃ 90th percentile and 
˂ 95th percentile), based on the recommenda-
tions for daily intake per age range (1C);
Water and salt supplementation should be given 
to children with CKD and polyuria to prevent in-
travascular compartment chronic depletion and to 
promote proper growth.
hyperurIceMIA
Hyperuricemia is a common finding in CKD pa-
tients, with reports of increased cardiovascular risk 
and CKD progression, which; however, still requi-
res confirmation.
There is insufficient evidence to support or re-
fute the use of serum uric acid reducing agents in 
CKD patients, even in symptomatic or asymptom-
atic hyperuricemia, with the aim of slowing CKD 
progression (no rating).
lifestyle
It is recommended that individuals with CKD are 
encouraged to engage in physical activity compati-
ble with their tolerance and cardiovascular health 
(in order to perform it for at least 30 minutes five 
times per week), reaching a healthy weight (BMI 
20 to 25 kg/m2, according to specific demographics 
of the country), and quit smoking (1D).
complicAtions AssociAteD with loss of RenAl 
function
CKD patients are prone to develop a variety of com-
plications, which reflect the loss of kidney endocrine 
and exocrine functions. The main ones are described 
as follows:
•	 Anemia: diagnosed in CKD adults and chil-
dren ˃ 15 years of age when Hb ˂ 13.0 g/dl 
in men and ˂ 12.0 g/dl in women (no rat-
ing). In children with CKD, anemia is diag-
nosed if the Hb concentration is ˂ 11.0 g/dL 
in children aged 0.5-5 years, ˂ 11.5 g/dL in 
children aged 5-12 years, and ˂ 12.0 g/dl in 
children aged 12-15 years (no rating).
In the treatment of CKD-related anemia, one 
should:
•	 Always evaluate secondary causes such as 
iron deficiency;
•	 Bear in mind that iron replacement is often 
effective in treating CKD anemia as initial 
treatment, leaving the clinician and patient 
to decide the route of administration (oral 
or IV);
•	 Do not use erythropoietin (EPO) in patients 
with active malignancy or history of recent 
treatment;
•	 Do not intentionally use EPO in the majority 
of patients with CKD to raise Hb above 
11.5 g/dL.
cKD-mbD incluDing lAboRAtoRy chAnges
Changes in bone mineral metabolism and altered 
calcium and phosphorus occur early in the course 
of CKD and progress with declining renal function. 
Despite the little evidence in CKD patients who are 
not undergoing dialysis:
•	 It is recommended to measure the levels of 
calcium, phosphorus, PTH and alkaline 
phosphatase at least once in adults with 
GFR ˂ 45 ml/min/1.73 m2 (G3b -G5) (1C);
•	 Do not perform routine tests to assess bone 
mineral density;
•	 Keep normal the phosphorus values of pa-
tients with GFR ˂ 45 ml/min/1.73 m2 
(G3b -G5) (2C);
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•	 Do not routinely prescribe vitamin D supple-
ments or its analogues in the absence of sus-
pected or documented deficiency, or to sup-
press high PTH concentrations in patients 
with CKD who are not on dialysis (2B);
•	 Do not prescribe bisphosphonate treatment 
for patients with GFR ˂ 30 ml/min/1.73 m2 
(G4-G5) (2B).
metAbolic AciDosis
The prevalence increases progressively with 
worsening of renal function, with detectable acido-
sis when GFR ˂ 40 ml/min/1.73 m2.
Chronic metabolic acidosis is associated with 
increased protein catabolism, uremic bone disease, 
muscle loss, chronic inflammation, impaired glu-
cose homeostasis, impaired cardiac function, CKD 
progression and increased mortality.
•	 In CKD patients with serum bicarbonate 
values ˂ 22 mmol/l, because of an increase 
in the risk of CKD progression and death, 
treatment should be made with bicarbonate 
supplementation per os, to keep normal lev-
els, should it not be a contraindication (2B).
Acute KiDney injuRy AnD cKD
We highlight acute kidney injury (AKI) as a com-
plication of CKD that needs to be properly mana-
ged, as well as its association with progression, it is 
recommended that patients with CKD be conside-
red as having an increased risk of developing AKI 
(1A). In fact, there are epidemiological basis for 
claiming that preexisting CKD predicts acute decli-
ne in renal function after exposure to radiological 
contrasts and major surgeries, among other medi-
cal conditions. The authors also stress the fact that 
there are still biomarkers capable of differentiating 
the “acute” from the “chronic” kidney disease in 
this context.
Whichever method is used to estimate GFR, 
hospitalization and mortality rates are higher in in-
dividuals with CKD.
RefeRRAl to expeRts AnD moDels of cARe
Early identification and referral of CKD patients 
have the potential to revert, delay or prevent the 
progression of the disease, becoming the focus of 
the international efforts in this field and having as 
its goals:
1. Provide specific therapy based on the 
diagnosis;
2. Slow/stop CKD progression;
3. Assess and treat comorbidities;
4. Prevent and treat cardiovascular disease;
5. Identify, prevent and treat specific CKD com-
plications (such as malnutrition, anemia, 
bone disease, acidosis);
6. Plan and prepare for RRT (choice of mode, 
access installation, preemptive transplanta-
tion, other);
7. Indicate psychological support, where appro-
priate, and provide conservative and pallia-
tive treatment.
It is recommended to refer CKD patients to spe-
cialist nephrology services in the following situa-
tions (1B):
1. AKI or abrupt and sustained decrease in 
GFR;
2. GFR < 30 ml/min/1.73 m2 (stages G4 -G5);
3. Significant albuminuria (CAR > 300 mg/g, al-
buminuria > 300 mg/24 h, which is equivalent 
to approximately PCR > 500 mg/g or 
proteinuria > 500 mg/24 h);
4. CKD progression;
5. Maintained and not readily explained hemat-
ic cylindruria and hematuria (> 20/pc);
6. CKD and treatment-refractory hypertension 
with four or more antihypertensive agents;
7. Persistent changes in serum potassium;
8. Hereditary kidney disease.
In general, the determinants of referral to the 
specialist can vary; however, it is recommended to 
do so in the event of: chronic or acute reduction in 
renal function, severe or poorly treated hyperten-
sion, severe electrolyte disturbances, significant ab-
normalities in urinary tract structure, or systemic 
diseases with probable renal involvement; the need 
for education in progressive diseases, performance 
and interpretation of renal biopsies, or to meet the 
psychological stress of parents and patients.
It is recommended that individuals with CKD 
should be kept under multidisciplinary care (2B).
Regarding the time to start RRT, it is suggested 
that dialysis is initiated when one or more of the 
following criteria is present: symptoms or signs at-
tributable to renal failure (serositis, acid-base and 
electrolyte disorders, pruritus); inability to control 
blood pressure or volume; progressive deterioration 
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of nutritional status refractory to dietary inter-
vention, or cognitive impairment. This happens 
often, but not invariably with GFR between 5 and 
10 ml/min/1.73 m2 (2B).
It is increasingly accepted the need to provide 
organized care for patients who are dying or who 
have chosen not to do dialysis or transplantation 
treatment, we must provide support for these pa-
tients and their families, keeping in mind that there 
is a wide range of needs for palliative treatment be-
fore death for patients with advanced CKD.
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